Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: Results from the French national healthcare database (the ANRS FANTASIO study)

B. ROLLAND ; C. LIONS ; V. DI BEO ; P. CARRIERI ; N. AUTHIER ; T. BARRÉ ; J. DELORME ; P. MATHURIN ; F. BAILLY ; C. PROTOPOPESCU ; F. MARCELLIN | 2022
Dans Harm Reduction Journal (Vol.19, 2022) Article : Périodique

Background: Opioid agonist therapy (OAT) is associated with reduced injection, reduced HCV transmission, and more opportunities to initiate hepatitis C virus (HCV) treatment in people who use drugs (PWUD). We aimed to study the extent to which a[...]

Plus d'info

Ajouter à la sélection

Lien externe

A call for mindfulness-based interventions for cannabis-use disorders [Commentary]

T. BARRÉ ; F. CHERIKH ; P. CARRIERI ; F. MARCELLIN | 2024
Dans Encéphale (L') (Vol.50, n°1, Février 2024) Article : Périodique

FRANÇAIS : La consommation de cannabis est de plus en plus libéralisée dans le monde, et on observe une prévalence croissante des troubles liés à l'usage de cannabis (TUC). Les quelques options thérapeutiques actuellement disponibles pour les T[...]

Plus d'info

Ajouter à la sélection

Lien externe

Cannabidiol use in France in 2022: Results from a nationwide representative sample of adults

T. BARRÉ ; E. LAHAIE ; V. DI BEO ; P. CARRIERI ; R. ANDLER ; V. NGUYEN THANH ; F. BECK | 2024
Dans Drug and Alcohol Review (Vol.43, n°5, July 2024) Article : Périodique

INTRODUCTION: Cannabidiol (CBD) is a non-intoxicating cannabis compound found in diverse commercial products worldwide. However, its use may not be fully harmless. Accordingly, it is important to document the prevalence of CBD use and user chara[...]

Plus d'info

Ajouter à la sélection

Lien externe

Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER)

S. ANTWERPES ; M. COSTA ; M. COSTE ; M. BUREAU ; G. MARADAN ; C. CUTARELLA ; J. LELOUTRE ; O. RICCOBONO-SOULIER ; S. HEDOIRE ; E. FROT ; F. VERNIER ; S. VASSAS-GOYARD ; T. BARRÉ ; D. CASANOVA ; P. CARRIERI | 2022
Dans Harm Reduction Journal (Vol.19, 2022) Article : Périodique

BACKGROUND: ETHER ("Education THEérapeutique pour la Réduction des dommages en alcoologie" or Therapeutic education for alcohol-related harm reduction) is a multicentre community-based mixed-methods study, which aims to evaluate the effectivenes[...]

Plus d'info

Ajouter à la sélection

Lien externe

Exclusive therapeutic use of cannabis in a large sample of daily cannabis users in France: A cross-sectional survey

M. BASTIEN ; S. MEZAACHE ; C. DONADILLE ; V. MARTIN ; L. APPEL ; M. LEBRUN ; L. BRIAND MADRID ; T. BARRÉ ; P. ROUX | 2024
Dans Journal of Psychoactive Drugs (Vol.56, n°3, July-August 2024) Article : Périodique

Many cannabis users report therapeutic benefits from cannabis consumption, even when not recommended by a physician. To date, few data on therapeutic users of cannabis in France are available. Using a cross-sectional survey held in 2020, we coll[...]

Plus d'info

Ajouter à la sélection

Lien externe

Exploring the medical cannabis prescribing behaviours of French general practitioners

T. BARRÉ ; H. VENTURINO ; V. DI BEO ; P. CARRIERI ; A. L. PELISSIER-ALICOT | 2023
Dans Drug and Alcohol Review (Vol.42, n°2, February 2023) Article : Périodique

Lettre à l'éditeur faisant référence à : Manoharan R., Kemper J., Young J. Exploring the medical cannabis prescribing behaviours of New Zealand physicians. Drug and Alcohol Review, 2022, Vol. 41, n° 6, p. 1355-1366. https://doi.org/10.1111/dar.[...]

Plus d'info

Ajouter à la sélection

Lien externe

Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project

T. ROJAS ROJAS ; V. DI BEO ; J. DELORME ; T. BARRÉ ; P. MATHURIN ; C. PROTOPOPESCU ; F. BAILLY ; M. COSTE ; N. AUTHIER ; M. P. CARRIERI ; B. ROLLAND ; F. MARCELLIN | 2019
Dans International Journal of Drug Policy (Vol.72, October 2019) Article : Périodique

Background: In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid ag[...]

Plus d'info

Ajouter à la sélection

A novel community-based therapeutic education program for reducing alcohol-related harms and stigma in people with alcohol use disorders: A quasi-experimental study (ETHER study)

T. BARRÉ ; C. RAMIER ; S. ANTWERPES ; M. COSTA ; M. BUREAU ; G. MARADAN ; V. DI BEO ; C. CUTARELLA ; J. LELOUTRE ; O. RICCOBONO-SOULIER ; S. HEDOIRE ; E. FROT ; F. VERNIER ; S. VASSAS-GOYARD ; S. DUFORT ; C. PROTOPOPESCU ; F. MARCELLIN ; D. CASANOVA ; M. COSTE ; P. CARRIERI | 2023
Dans Drug and Alcohol Review (Vol.42, n°3, March 2023) Article : Périodique

INTRODUCTION: Alcohol use disorder (AUD) is associated with a significant disease burden in France, where alcohol use is deeply rooted in culture. However, the treatment gap is large because of several barriers, including stigmatisation and drin[...]

Plus d'info

Ajouter à la sélection

Lien externe

Pratique de l'ATU de cohorte de la naloxone intranasale (Nalscue®) : mise en place dans un CSAPA parisien

T. BARRÉ ; F. VORSPAN ; M. FORTIAS ; M. VEYRIER ; P. CAVAGNA ; J. AZUAR ; L. NICOLAS ; F. NACCACHE ; H. BARRETEAU ; F. BELLIVIER ; V. BLOCH | 2018
Dans Therapies (Vol.73, n°6, Décembre 2018) Article : Périodique

FRANÇAIS : La naloxone intranasale vise à réduire la mortalité pré-hospitalière par overdose des usagers de drogues opioïdes. En France, sa délivrance nominative est possible depuis juillet 2016 dans le cadre d'une autorisation temporaire d'uti[...]

Plus d'info

Ajouter à la sélection

Prevalence and factors associated with tobacco and cannabis co-use in France: Results from a national representative survey

T. BARRÉ ; V. DI BEO ; C. PROTOPOPESCU ; E. LAHAIE ; R. ANDLER ; V. NGUYEN THANH ; A. PASQUEREAU ; P. CARRIERI ; F. BECK | 2025
Dans Drug and Alcohol Dependence Reports (Vol.17, December 2025) Article : Périodique

Background and aims: Tobacco use is a leading global risk factor for premature mortality. Cannabis-related harms are well documented, and its co-use with tobacco may hinder smoking cessation efforts. Moreover, tobacco use may amplify certain can[...]

Plus d'info

Ajouter à la sélection

Lien externe

Recreational nitrous oxide use in France in 2022: Results from a nationwide representative sample of adults

T. BARRÉ ; E. LAHAIE ; V. DI BEO ; P. CARRIERI ; R. ANDLER ; V. NGUYEN THANH ; F. BECK | 2025
Dans Drug and Alcohol Review (Vol.44, n°4, May 2025) Article : Périodique

Introduction: The increasing heavy and sustained use of nitrous oxide (N2O) for recreational purposes in several countries is a growing public health issue, as it can cause neuropathy and other harms. Documenting recreational N2O use prevalence [...]

Plus d'info

Ajouter à la sélection

Lien externe

Relationships between motives for cannabis and cannabidiol use in people who co-use: Results from the European Web Survey on Drugs

D. FORTIN ; V. LEROY ; P. CARRIERI ; J. MATIAS ; T. BARRÉ | 2025
Dans Drug and Alcohol Review (Vol.44, n°6, September 2025) Article : Périodique

INTRODUCTION: Cannabis is one of the most commonly used psychoactive substances globally. Cannabidiol (CBD) is a non-intoxicating cannabis compound increasingly used for various purposes, especially among cannabis users. However, to date, there [...]

Plus d'info

Ajouter à la sélection

Lien externe

Screening and care for alcohol use disorder in France: expectations, barriers and levers using a mixed-methods approach

M. COSTA ; T. BARRÉ ; M. COSTE ; I. YAYA ; C. BERENGER ; M. TANTI ; C. CUTARELLA ; M. MORA ; P. POLOMENI ; M. MAYNARD ; D. TEUMA ; M. BAZIN ; G. MARADAN ; P. ROUX ; P. M. CARRIERI | 2020
Dans BMC Public Health (Vol.20, 2020) Article : Périodique

BACKGROUND: The widespread under-screening and under-treatment of alcohol use disorder (AUD) contributes to its health and socioeconomic burden. We conducted a mixed-methods (qualitative and qualitative) study in people with alcohol use disorder[...]

Plus d'info

Ajouter à la sélection

Lien externe

Screening for alcohol use in primary care: assessing French general practitioner practices

T. BARRÉ ; V. DI BEO ; P. ROUX ; A. MOURAD ; P. VERGER ; L. FRESSARD ; T. HERAULT ; J. F. BUYCK ; F. BECK ; P. CARRIERI | 2023
Dans Alcohol and Alcoholism (Vol.58, n°6, November 2023) Article : Périodique

Alcohol use is a leading risk factor for premature death and disability. To tackle this issue, more systematic and accurate screening for at-risk consumption is needed in healthcare systems, especially by general practitioners (GPs). We assessed[...]

Plus d'info

Ajouter à la sélection

Lien externe

Screening for tobacco and cannabis use by general practitioners: A French nationwide representative survey

T. BARRÉ ; V. DI BEO ; A. MOURAD ; P. CARRIERI ; G. MARADAN ; L. FRESSARD ; T. HERAULT ; J. F. BUYCK ; P. VERGER ; F. BECK | 2025
Dans International Journal of Mental Health and Addiction (Vol.23, n°5, October 2025) Article : Périodique

Screening is a crucial step in the cascade of care for people who smoke tobacco or cannabis. In France, general practitioners (GPs) are considered a pillar of tobacco control, and under National Authority of Health guidelines, they are expected [...]

Plus d'info

Ajouter à la sélection

Lien externe